IP Library › Patent Application 14151632
Patent Application
App. No. 14/151,632

LIPOSOMES USEFUL FOR DRUG DELIVERY TO THE BRAIN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/151,632
Abstract

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. The present invention also provides for the methods and kits for the delivery of liposomal compositions to the brain.

Claims (12)

1 . A fluid conduit, adapted for placement within the brain tissue of a mammal and containing a formulation comprising a liposome in an aqueous medium, wherein the liposome comprises an aqueous interior space that contains sucrose octasulfate and an cationic antineoplastic agent.

2 . The conduit of claim 1 , wherein the formulation further comprises a contrast agent.

3 . The conduit of claim 2 , wherein the contrast agent is suitable for X-ray imaging or magnetic resonance imaging (MRI).

4 . The conduit of claim 1 , wherein the conduit is placed in brain tissue comprising a brain tumor.

5 . The conduit of claim 1 wherein the cationic antineoplastic agent is a camptothecin.

6 . The conduit of claim 1 wherein the cationic antineoplastic agent is irinotecan.

7 . An infusion catheter or cannula having a tip, wherein the catheter or cannula contains a formulation comprising a liposome in an aqueous medium, wherein the liposome comprises an aqueous interior space that contains sucrose octasulfate and an cationic antineoplastic agent, and wherein the tip is adapted for placement within the brain of a mammal.

8 . The infusion catheter or cannula of claim 7 , wherein the tip is positioned within a brain tumor within the brain of the mammal.

9 . The infusion catheter or cannula of claim 7 , wherein the formulation further contains a contrast agent.

10 . The infusion catheter or cannula of claim 9 , wherein the contrast agent is suitable for X-ray imaging or magnetic resonance imaging (MRI).

11 . The infusion catheter or cannula of claim 7 wherein the cationic antineoplastic agent is a camptothecin.

12 . The conduit of claim 7 wherein the cationic antineoplastic agent is irinotecan.

Assignments (6)
CHANGE OF ADDRESS OF ASSIGNEE Recorded May 17, 2017
From: MERRIMACK PHARMACEUTICALS, INC.
To: IPSEN BIOPHARM LTD.
Reel/Frame 042522/0334 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2017
From: MERRIMACK PHARMACEUTICALS, INC.
To: IPSEN BIOPHARM LTD.
Reel/Frame 042377/0696 →
RELEASE OF SECURITY INTEREST Recorded Apr 14, 2017
From: U.S. BANK NATIONAL ASSOCIATION
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 042254/0349 →
SECURITY INTEREST Recorded Dec 28, 2015
From: MERRIMACK PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 037394/0285 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2014
From: HONG, KEELUNG; DRUMMOND, DARYL C.; KIRPOTIN, DMITRI
To: HERMES BIOSCIENCES, INC.
Reel/Frame 033623/0874 →
MERGER Recorded Aug 27, 2014
From: HERMES BIOSCIENCES, INC.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 033623/0992 →